Related Experiment Video
Updated: Oct 22, 2025

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Bothrops Jararaca Snake Venom Modulates Key Cancer-Related Proteins in Breast Tumor Cell Lines
Carolina Yukiko Kisaki1, Stephanie Santos Suehiro Arcos1, Fabio Montoni1
1Laboratory of Applied Toxinology (LETA) and Center of Toxins, Immune-Response and Cell Signaling (CeTICS), Butantan Institute, São Paulo 05503-900, Brazil.
Abstract:
Cancer is characterized by the development of abnormal cells that divide in an uncontrolled way and may spread into other tissues where they may infiltrate and destroy normal body tissue. Several previous reports have described biochemical anti-tumorigenic properties of crude snake venom or its components, including their capability of inhibiting cell proliferation and promoting cell death. However, to the best of our knowledge, there is no work describing cancer cell proteomic changes following treatment with snake venoms. In this work we describe the quantitative changes in proteomics of MCF7 and MDA-MB-231 breast tumor cell lines following treatment with Bothrops jararaca snake venom, as well as the functional implications of the proteomic changes. Cell lines were treated with sub-toxic doses at either 0.63 μg/mL (low) or 2.5 μg/mL (high) of B. jararaca venom for 24 h, conditions that cause no cell death per se. Proteomics analysis was conducted on a nano-scale liquid chromatography coupled on-line with mass spectrometry (nLC-MS/MS). More than 1000 proteins were identified and evaluated from each cell line treated with either the low or high dose of the snake venom. Protein profiling upon venom treatment showed differential expression of several proteins related to cancer cell metabolism, immune response, and inflammation. Among the identified proteins we highlight histone H3, SNX3, HEL-S-156an, MTCH2, RPS, MCC2, IGF2BP1, and GSTM3. These data suggest that sub-toxic doses of B. jararaca venom have potential to modulate cancer-development related protein targets in cancer cells. This work illustrates a novel biochemical strategy to identify therapeutic targets against cancer cell growth and survival.
Insights
This study reveals that sub-toxic doses of Bothrops jararaca snake venom alter cancer cell proteomics, modulating proteins involved in metabolism, immune response, and inflammation. These findings suggest novel therapeutic targets for cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Proteomics
Background:
- Cancer is defined by uncontrolled cell division and tissue invasion.
- Snake venom components exhibit anti-tumorigenic properties, inhibiting proliferation and promoting cell death.
- Proteomic changes in cancer cells after snake venom treatment remain largely unexplored.
Purpose of the Study:
- To investigate quantitative proteomic changes in breast cancer cell lines (MCF7 and MDA-MB-231) after treatment with Bothrops jararaca snake venom.
- To identify functional implications of these proteomic alterations.
- To explore novel therapeutic targets for cancer treatment.
Main Methods:
- Treatment of MCF7 and MDA-MB-231 cell lines with sub-toxic doses (0.63 μg/mL and 2.5 μg/mL) of B. jararaca venom for 24 hours.
- Proteomics analysis using nano-scale liquid chromatography coupled with mass spectrometry (nLC-MS/MS).
- Identification and evaluation of over 1000 proteins from each cell line.
Main Results:
- Differential expression of numerous proteins related to cancer cell metabolism, immune response, and inflammation was observed.
- Key proteins identified include histone H3, SNX3, HEL-S-156an, MTCH2, RPS, MCC2, IGF2BP1, and GSTM3.
- Sub-toxic venom doses modulated protein expression without causing cell death.
Conclusions:
- Sub-toxic doses of B. jararaca venom can modulate protein targets crucial for cancer development.
- This study presents a novel biochemical strategy for identifying therapeutic targets against cancer cell growth and survival.
- The findings suggest potential for snake venom-derived compounds in cancer therapy.
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

